Board shakeup at Dermata (DRMA) as director Mary Fisher plans exit

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. reported that director Mary Fisher has notified the company she will resign from its Board of Directors, including all committee roles, effective March 31, 2026. The filing states her decision is tied to her employer’s recent acquisition, which will no longer permit her to serve on Dermata’s board.

The company notes that her resignation is not due to any disagreement with Dermata or its management regarding operations, policies, or practices. Once her resignation becomes effective, the size of the Board will be reduced from eight to seven members.

false 0001853816 0001853816 2026-02-23 2026-02-23 0001853816 DRMA:CommonStockParValue0.0001PerShareMember 2026-02-23 2026-02-23 0001853816 DRMA:WarrantsExercisableForOneShareOfCommonStockMember 2026-02-23 2026-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 23, 2026

DERMATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40739		86-3218736
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

3525 Del Mar Heights Rd., #322 San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

(858) 800-2543

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		DRMA		The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock		DRMAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 23, 2026, Mary Fisher provided Dermata Therapeutics, Inc. (the “Company”) with notice of her resignation from the Board of Directors (the “Board”), including from her role on any committees thereof, effective March 31, 2026. Ms. Fisher’s resignation was not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies or practices. Ms. Fisher resigned from the Board in order to comply with her employer recently being acquired and no longer permitting her to serve on the Company’s Board. Upon the effectiveness of Ms. Fisher’s resignation, the size of the Board will be reduced from eight to seven.

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DERMATA THERAPEUTICS, INC.
Dated: February 25, 2026	By:	/s/ Gerald T. Proehl
	Name:	Gerald T. Proehl
	Title:	President, Chairman and Chief Executive Officer

-3-

FAQ

Why did Mary Fisher resign from Dermata Therapeutics (DRMA)’s Board?

Mary Fisher resigned because her employer was recently acquired and the new ownership will no longer permit her to serve on Dermata’s Board. The company states her resignation was not due to any disagreement over operations, policies, or practices with Dermata or its management.

When will Mary Fisher’s resignation from Dermata Therapeutics’ Board become effective?

Mary Fisher’s resignation from Dermata Therapeutics’ Board becomes effective on March 31, 2026. She notified the company of her decision on February 23, 2026, and will leave both the Board and its committees as of that effective date.

Did Mary Fisher have any disagreements with Dermata Therapeutics (DRMA) leading to her resignation?

The company states that Mary Fisher’s resignation was not the result of any disagreement with Dermata Therapeutics or its management. This includes no disputes regarding the company’s operations, policies, or practices, and the decision is attributed solely to restrictions from her employer’s new ownership.

How does Mary Fisher’s resignation affect the size of Dermata Therapeutics’ Board?

Upon the effectiveness of Mary Fisher’s resignation on March 31, 2026, Dermata Therapeutics’ Board size will be reduced from eight to seven directors. The filing does not describe any replacement appointment, only the reduction in total board seats following her departure.

What SEC item does Dermata Therapeutics use to disclose Mary Fisher’s resignation?

Dermata Therapeutics discloses Mary Fisher’s resignation under Item 5.02, which covers departures of directors or certain officers, elections of directors, appointments of certain officers, and compensatory arrangements. This item is used when board composition or key leadership roles change.

Who signed the Dermata Therapeutics (DRMA) filing announcing Mary Fisher’s resignation?

The filing was signed on behalf of Dermata Therapeutics by Gerald T. Proehl, who is identified as President, Chairman and Chief Executive Officer. His signature confirms the company’s authorization and certification of the information regarding Mary Fisher’s planned resignation from the Board.

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.7 KB
• EX-101 XBRL DEFINITION FILE 26.0 KB
• EX-101 XBRL LABEL FILE 35.9 KB
• EX-101 XBRL PRESENTATION FILE 24.7 KB